FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213785951> ?p ?o ?g. }

• W3213785951 endingPage "161" @default.
• W3213785951 startingPage "154" @default.
• W3213785951 abstract "SARS-CoV-2 has infected over 200 million people worldwide, resulting in more than 4 million deaths. Randomized controlled trials are the single best tool to identify effective treatments against this novel pathogen.To describe the characteristics of randomized controlled trials of treatments for COVID-19 in the United States launched in the first 9 months of the pandemic. Design, Setting, and Participants We conducted a cross-sectional study of all completed or actively enrolling randomized, interventional, clinical trials for the treatment of COVID-19 in the United States registered on www.clinicaltrials.gov as of August 10, 2020. We excluded trials of vaccines and other interventions intended to prevent COVID-19. Main Outcomes and Measures We used descriptive statistics to characterize the clinical trials and the statistical power for the available studies. For the late-phase trials (i.e., phase 3 and 2/3 studies), we compared the geographic distribution of the clinical trials with the geographic distribution of people diagnosed with COVID-19.We identified 200 randomized controlled trials of treatments for people with COVID-19. Across all trials, 87 (43.5%) were single-center, 64 (32.0%) were unblinded, and 80 (40.0%) were sponsored by industry. The most common treatments included monoclonal antibodies (N=46 trials), small molecule immunomodulators (N=28), antiviral medications (N=24 trials), and hydroxychloroquine (N=20 trials). Of the 9 trials completed by August 2020, the median sample size was 450 (IQR 67-1113); of the 191 ongoing trials, the median planned sample size was 150 (IQR 60-400). Of the late-phase trials (N=54), the most common primary outcome was a severity scale (N=23, 42.6%), followed by a composite of mortality and ventilation (N=10, 18.5%), and mortality alone (N=6, 11.1%). Among these late-phase trials, all trials of antivirals, monoclonal antibodies, or chloroquine/hydroxychloroquine had a power of less than 25% to detect a 20% relative risk reduction in mortality. Had the individual trials for a given class of treatments instead formed a single trial, the power to detect that same reduction in mortality would have been greater than 98%. There was large variability in access to trials with the highest number of trials per capita in the Northeast and the lowest in the Midwest.A large number of randomized trials were launched early in the pandemic to evaluate treatments for COVID-19. However, many trials were underpowered for important clinical endpoints and substantial geographic disparities were observed, highlighting the importance of improving national clinical trial infrastructure." @default.
• W3213785951 created "2021-11-22" @default.
• W3213785951 creator A5003249779 @default.
• W3213785951 creator A5005374298 @default.
• W3213785951 creator A5005821516 @default.
• W3213785951 creator A5021872190 @default.
• W3213785951 creator A5023244444 @default.
• W3213785951 creator A5043698578 @default.
• W3213785951 creator A5089776227 @default.
• W3213785951 date "2021-11-09" @default.
• W3213785951 modified "2023-10-18" @default.
• W3213785951 title "The Landscape of COVID-19 Research in the United States: a Cross-sectional Study of Randomized Trials Registered on ClinicalTrials.Gov" @default.
• W3213785951 cites W1973679249 @default.
• W3213785951 cites W2068594674 @default.
• W3213785951 cites W2145568247 @default.
• W3213785951 cites W2315579559 @default.
• W3213785951 cites W2413861456 @default.
• W3213785951 cites W2506392919 @default.
• W3213785951 cites W3001897055 @default.
• W3213785951 cites W3008443627 @default.
• W3213785951 cites W3025152092 @default.
• W3213785951 cites W3027630905 @default.
• W3213785951 cites W3032677067 @default.
• W3213785951 cites W3082051346 @default.
• W3213785951 cites W3082355253 @default.
• W3213785951 cites W3083996275 @default.
• W3213785951 cites W3099995976 @default.
• W3213785951 cites W3112030067 @default.
• W3213785951 doi "https://doi.org/10.1007/s11606-021-07167-9" @default.
• W3213785951 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8577643" @default.
• W3213785951 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34755268" @default.
• W3213785951 hasPublicationYear "2021" @default.
• W3213785951 type Work @default.
• W3213785951 sameAs 3213785951 @default.
• W3213785951 citedByCount "3" @default.
• W3213785951 countsByYear W32137859512022 @default.
• W3213785951 countsByYear W32137859512023 @default.
• W3213785951 crossrefType "journal-article" @default.
• W3213785951 hasAuthorship W3213785951A5003249779 @default.
• W3213785951 hasAuthorship W3213785951A5005374298 @default.
• W3213785951 hasAuthorship W3213785951A5005821516 @default.
• W3213785951 hasAuthorship W3213785951A5021872190 @default.
• W3213785951 hasAuthorship W3213785951A5023244444 @default.
• W3213785951 hasAuthorship W3213785951A5043698578 @default.
• W3213785951 hasAuthorship W3213785951A5089776227 @default.
• W3213785951 hasBestOaLocation W32137859511 @default.
• W3213785951 hasConcept C105795698 @default.
• W3213785951 hasConcept C126322002 @default.
• W3213785951 hasConcept C129848803 @default.
• W3213785951 hasConcept C168563851 @default.
• W3213785951 hasConcept C2779123688 @default.
• W3213785951 hasConcept C2779134260 @default.
• W3213785951 hasConcept C3008058167 @default.
• W3213785951 hasConcept C33923547 @default.
• W3213785951 hasConcept C524204448 @default.
• W3213785951 hasConcept C535046627 @default.
• W3213785951 hasConcept C71924100 @default.
• W3213785951 hasConcept C89623803 @default.
• W3213785951 hasConceptScore W3213785951C105795698 @default.
• W3213785951 hasConceptScore W3213785951C126322002 @default.
• W3213785951 hasConceptScore W3213785951C129848803 @default.
• W3213785951 hasConceptScore W3213785951C168563851 @default.
• W3213785951 hasConceptScore W3213785951C2779123688 @default.
• W3213785951 hasConceptScore W3213785951C2779134260 @default.
• W3213785951 hasConceptScore W3213785951C3008058167 @default.
• W3213785951 hasConceptScore W3213785951C33923547 @default.
• W3213785951 hasConceptScore W3213785951C524204448 @default.
• W3213785951 hasConceptScore W3213785951C535046627 @default.
• W3213785951 hasConceptScore W3213785951C71924100 @default.
• W3213785951 hasConceptScore W3213785951C89623803 @default.
• W3213785951 hasIssue "1" @default.
• W3213785951 hasLocation W32137859511 @default.
• W3213785951 hasLocation W32137859512 @default.
• W3213785951 hasLocation W32137859513 @default.
• W3213785951 hasOpenAccess W3213785951 @default.
• W3213785951 hasPrimaryLocation W32137859511 @default.
• W3213785951 hasRelatedWork W2068981458 @default.
• W3213785951 hasRelatedWork W2162982134 @default.
• W3213785951 hasRelatedWork W2520571625 @default.
• W3213785951 hasRelatedWork W2789089580 @default.
• W3213785951 hasRelatedWork W2796060362 @default.
• W3213785951 hasRelatedWork W3027791452 @default.
• W3213785951 hasRelatedWork W3110506613 @default.
• W3213785951 hasRelatedWork W3124402827 @default.
• W3213785951 hasRelatedWork W3149354770 @default.
• W3213785951 hasRelatedWork W3153679424 @default.
• W3213785951 hasVolume "37" @default.
• W3213785951 isParatext "false" @default.
• W3213785951 isRetracted "false" @default.
• W3213785951 magId "3213785951" @default.
• W3213785951 workType "article" @default.